Sudarshan Pharma Industries Ltd
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
- Market Cap ₹ 669 Cr.
- Current Price ₹ 27.8
- High / Low ₹ 53.5 / 5.82
- Stock P/E 37.1
- Book Value ₹ 5.46
- Dividend Yield 0.00 %
- ROCE 18.6 %
- ROE 16.2 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 69.8% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.0% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 148 | 193 | 357 | 461 | 464 | 505 | |
| 143 | 186 | 346 | 446 | 441 | 465 | |
| Operating Profit | 5 | 7 | 11 | 15 | 23 | 40 |
| OPM % | 3% | 4% | 3% | 3% | 5% | 8% |
| 0 | 0 | 0 | 1 | 3 | -0 | |
| Interest | 3 | 3 | 3 | 5 | 9 | 16 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 2 | 4 | 7 | 9 | 15 | 22 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 26% |
| 1 | 3 | 5 | 7 | 11 | 16 | |
| EPS in Rs | 0.13 | 0.28 | 0.54 | 0.29 | 0.48 | 0.66 |
| Dividend Payout % | 0% | 0% | 0% | 10% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 12% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 50% |
| TTM: | 57% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 255% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 13% |
| Last Year: | 16% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 |
| 21 | 30 | 31 | 34 | 105 | 171 | |
| 18 | 47 | 77 | 97 | 67 | 100 | |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 402 |
| 6 | 6 | 6 | 20 | 26 | 24 | |
| CWIP | 0 | 0 | 1 | 0 | 2 | 6 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 |
| 53 | 93 | 131 | 200 | 242 | 342 | |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 402 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 1 | 3 | -4 | -29 | 6 | ||
| -3 | -1 | -1 | -26 | -5 | ||
| -0 | -1 | 4 | 66 | -12 | ||
| Net Cash Flow | -2 | -0 | -1 | 11 | -12 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 66 | 114 | 75 | 64 | 96 | |
| Inventory Days | 46 | 49 | 51 | 63 | 74 | |
| Days Payable | 40 | 91 | 80 | 78 | 49 | |
| Cash Conversion Cycle | 72 | 72 | 46 | 50 | 122 | |
| Working Capital Days | 69 | 69 | 54 | 71 | 137 | |
| ROCE % | 15% | 19% | 15% | 14% |
Documents
Announcements
-
Financial Results For The Financial Year Ended March 31, 2025
14h - Audited FY25 financials; preferential warrants issued; acquired subsidiaries; insurance claim rejected; litigation award received.
-
Board Meeting Intimation for Approval Of Financial Results On Thursday, 24-04-2025
21 Apr - Board meeting on April 28, 2025, to approve financial results; trading window closed from March 21, 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
21 Apr - Certificate filed for securities dematerialization/rematerialization for quarter ended March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
3 Apr - Acquired 51% stake in Ishwari Healthcare for Rs. 1.5 Crore.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
1 Apr - Rescinded appointment of CFO and retention of Joint MD.
Business Overview:[1][2]
SPIL does jobwork manufacturing in pharmaceutical Items and trading in chemicals and solvents in India. It
specializes in a host of products from rock chemicals intermediates and API to finish formulations and fully
integrated pharmaceutical and chemicals